This Week in Virology: Episode 1184 - A Discussion on Emerging Viral Threats and Public Health
0:01:03 Introduction and Theme: The episode begins with introductions and sets the theme of "knocking at the gate," emphasizing perseverance in addressing viral threats.
0:01:59 Childhood Diseases Resurgence: An article from the New York Times highlights a concerning rise in childhood diseases like whooping cough, with over 32,000 cases in 2024 in the US, attributed partly to budget cuts in the 1980s affecting vaccination rates.
0:03:34 Polio Vaccination Concerns: Another New York Times article discusses how lagging polio vaccination could lead to a resurgence, particularly with the use of oral polio vaccine (OPV) in some parts of the world.
0:06:07 Polio Virus vs. Poliomyelitis: The hosts clarify the crucial distinction between polio virus (which can circulate even with inactivated polio vaccine (IPV) use) and poliomyelitis (the disease, which can be eradicated).
0:06:58 Issues with OPV: The continued use of OPV, especially type 2, is highlighted as a problem because it can revert to a virulent form and cause paralysis in unvaccinated individuals.
0:10:15 Norovirus Surge: An article from Science discusses the surge of norovirus, dubbed the "Ferrari of viruses," in the Northern Hemisphere, with a significant increase in cases and wastewater detection levels.
0:13:06 Norovirus: Background and Transmission: The hosts discuss norovirus's characteristics, including its high transmissibility through various routes (vomiting, contaminated surfaces, food, water), and its resistance to alcohol-based sanitizers.
0:16:56 Reasons for Norovirus Surge: The surge is attributed to increased social gatherings post-COVID-19 restrictions and the reliance on alcohol-based hand sanitizers instead of proper handwashing with soap and water.
0:20:56 Pneumococcal Vaccination Recommendations: The Advisory Committee on Immunization Practices (ACIP) recommends a single dose of pneumococcal conjugate vaccine (PCV) for all adults 50 and over.
0:22:15 Avian Influenza Update: A brief update on a presumptive case of H5N1 avian flu in a child, with a reminder about the high mortality associated with certain strains in cases of direct avian-to-human transmission.
0:22:56 Influenza A and Antiviral Discussion: Influenza A is identified as the primary respiratory pathogen currently circulating, with high levels across most of the US.
0:23:45 Zofluzia vs. Tamiflu: A meta-analysis suggests that Xofluza (baloxavir marboxil) may be more effective than Tamiflu (oseltamivir) in reducing symptom duration and has fewer adverse events, but resistance emergence is a concern.
0:27:27 Issues with Meta-Analysis: The hosts critique the meta-analysis for including studies where treatment was started beyond the optimal 48-hour window, potentially skewing the results.
0:28:18 Benefits of Early Antiviral Treatment: Early initiation of antiviral treatment, ideally within 48 hours, is emphasized for maximum effectiveness.
0:30:10 RSV Update: Respiratory Syncytial Virus (RSV) levels are high, with a pattern similar to the previous year, peaking around January.
0:30:43 COVID-19 Update: COVID-19 wastewater levels remain high, and an increase in deaths is observed in several states.
0:31:13 COVID-19 Treatment: Paxlovid remains the first-line treatment for COVID-19, with other options including remdesivir, molnupiravir, and convalescent plasma.
0:31:53 Long COVID Studies: Two studies on long COVID are discussed, one suggesting potential benefits of SARS-CoV-2 vaccination in reducing symptom severity, and the other highlighting substantial impairment of verbal short-term and working memory in individuals with neurological post-COVID syndrome.
0:36:06 Importance of Vaccination and Public Health Measures: The episode concludes by emphasizing the importance of vaccination, early testing, and appropriate treatment in mitigating the impact of viral infections.
0:36:17 MicrobeTV Fundraiser: The episode ends with a reminder about the MicrobeTV fundraiser and a request for listener donations.
0:36:38 Listener Questions: Dr. Griffin answers listener questions about Pemgarda for immunocompromised individuals, the potential mortality rate of an avian flu pandemic, combination therapy for COVID-19, and the importance of proper diagnosis of penicillin allergies. He also addresses a claim of hospitals in China being overwhelmed by a new human metapneumovirus, stating that there is currently no evidence to support this claim.